1. Home
  2. DCBO vs AKBA Comparison

DCBO vs AKBA Comparison

Compare DCBO & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Docebo Inc.

DCBO

Docebo Inc.

HOLD

Current Price

$21.05

Market Cap

723.3M

Sector

N/A

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.56

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DCBO
AKBA
Founded
2016
2007
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
723.3M
729.1M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
DCBO
AKBA
Price
$21.05
$1.56
Analyst Decision
Buy
Strong Buy
Analyst Count
7
6
Target Price
$35.57
$6.25
AVG Volume (30 Days)
98.3K
5.2M
Earning Date
11-07-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
32.42
N/A
EPS
0.74
N/A
Revenue
$236,691,000.00
$225,071,000.00
Revenue This Year
$13.00
$53.38
Revenue Next Year
$8.37
$30.53
P/E Ratio
$26.72
N/A
Revenue Growth
13.16
32.49
52 Week Low
$20.20
$1.49
52 Week High
$50.80
$4.08

Technical Indicators

Market Signals
Indicator
DCBO
AKBA
Relative Strength Index (RSI) 29.93 31.15
Support Level $20.47 $1.52
Resistance Level $21.37 $1.65
Average True Range (ATR) 0.97 0.12
MACD 0.01 0.01
Stochastic Oscillator 12.59 18.75

Price Performance

Historical Comparison
DCBO
AKBA

About DCBO Docebo Inc.

Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: